Phase II trial of multi-tyrosine kinase inhibitor ESK981 in combination with PD-1 inhibitor nivolumab in patients with metastatic castration-resistant prostate cancer
Elisabeth I. Heath, Wei Chen, Jae Eun Choi, Kimberlee Dobson, Melanie Smith, Tomasz Maj, Ilona Kryczek, Weiping Zou, Arul M. Chinnaiyan, Yuanyuan Qiao
Topics & Concepts
NivolumabMedicineProstate cancerTyrosine-kinase inhibitorInternal medicineOncologyTyrosine kinaseProstateCancer researchImmunotherapyCancerReceptorProstate Cancer Treatment and ResearchCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and Studies